



SECTOR COMMENT

3 April 2020

Rate this Research

Analyst Contacts

Daniel Steingart, CFA +1.949.429.5355
 VP-Sr Credit Officer
 daniel.steingart@moodys.com

Lisa Goldstein +1.212.553.4431
 Associate Managing Director
 lisa.goldstein@moodys.com

Kendra M. Smith +1.212.553.4807
 MD-Public Finance
 kendra.smith@moodys.com

CLIENT SERVICES

Americas	1-212-553-1653
Asia Pacific	852-3551-3077
Japan	81-3-5408-4100
EMEA	44-20-7772-5454

Not-for-profit hospitals – US

Federal coronavirus aid package provides modest relief; ratings reflect support

The Coronavirus Aid, Relief and Economic Stimulus (CARES) Act, the \$2.2 trillion federal package signed into law on March 27, contains several provisions for US not-for-profit hospitals that will support their operations and help provide access to critical supplies. Key provisions include \$100 billion in funding to compensate for lost revenue and coronavirus preparation costs, increased Medicare reimbursement, and liquidity support through advances on future Medicare reimbursement. While the extraordinary level of federal aid offers the sector some relief, however, it is unlikely to fully cover the material revenue decline facing hospitals as a result of the pandemic, and cash flow will likely be materially lower for the next several months. As such, our outlook for the sector remains negative.

Federal package's \$100 billion fund will provide relief for hospitals though it will not fully compensate for lost revenue

The \$100 billion fund contained in the CARES Act is intended to provide relief to hospitals, supporting their operations and providing access to critical supplies. However, it is unlikely to fully compensate the sector for the two main financial challenges facing providers as a result of the coronavirus outbreak. These challenges are i) a material decline in revenue and cash flow as profitable elective surgeries, procedures and other services are postponed to preserve resources and avoid spreading the virus, and ii) difficulty curbing expenses as surge preparation costs offset any expense reductions from postponed or canceled services.

Postponed services will likely reduce hospital revenue by 25%-40% per month on average and strain cash flow significantly, according to early anecdotal information. This reduction is occurring even in regions and hospitals that, to date, have not seen many coronavirus patients. Many states have mandated that hospitals suspend nonessential services for an indefinite period, creating uncertainty over when hospitals can resume providing services. Moreover, hospitals in regions with large outbreaks are already experiencing, or will soon experience, a surge in coronavirus patients, placing additional strain on operations and supplies and increasing labor expenses.

While the \$100 billion provides some compensation, it will likely be insufficient to fully cover this lost revenue, particularly if the outbreak is sustained over a long period, and elective and other nonessential care remains suspended into late spring or summer. Based on data from the Centers for Medicare and Medicaid Services (CMS), \$100 billion is the approximate national spend on hospital services per month. The \$100 billion in the federal package is intended not only to compensate for lost revenue but also to cover emergency preparedness. Given that affected services will almost certainly be suspended for over a month, and that

the \$100 billion is available to not only hospitals but other non-hospital healthcare providers (such as nursing homes and clinics), it will not likely be enough to cover lost revenue from suspended services. Additionally, the application process and timing of such funds is unclear.

Advances on future Medicare reimbursement will provide fastest liquidity relief

Expansion of the Medicare Accelerated and Advance Payment Program, as proposed, will provide the fastest liquidity relief to hospitals because it expands on an existing program. The program allows hospitals to receive six-month's worth in expected future Medicare reimbursement in cash today, with repayments deducted from future Medicare reimbursement over the next year. Medicare is the primary payor for about half of all hospital charges and we estimate this program could provide cash payments equal to about 10% of a hospital's annual revenue, making the potential liquidity support from this program significant.

Deferral of payroll taxes, increased reimbursement for coronavirus cases will also support liquidity

Several other provisions of the CARES Act are intended to benefit hospitals and support liquidity over the next several months, including the ability to defer the employer portion of federal payroll taxes. Over the second half of 2020, the suspension of Medicare sequestration, which effectively increases all Medicare reimbursement to hospitals by 2%, and a 20% increase in Medicare reimbursement to hospitals for coronavirus patients will also provide some financial support.

Other federal actions will also benefit hospitals

Legislation passed two weeks ago increased the federal share of Medicaid funding (FMAP) by 6.2%. Although less than requested by state governors, the increase will alleviate states' Medicaid spending, which is likely to grow substantially as job losses increase the number of individuals qualifying for Medicaid. Support from the military, including hospital ships and plans by the Army Corps of Engineers to build hundreds of temporary hospitals, will allow hospitals to focus on the sickest patients. Nevertheless, the surge in patients in the most affected areas is still likely to overwhelm hospitals in those regions.

Ratings will incorporate support provided by the CARES Act

Our credit analysis and recent ratings incorporate the level of support provided by the CARES Act for the hospital sector. For example, [Bon Secours Mercy Health](#), a \$10 billion revenue multi-site health system, was upgraded recently to A1 stable from A2 positive. The system's ample liquidity of over \$5 billion and likely benefits of additional funding via the CARES Act should allow it to manage the impact of COVID-19, along with other factors.

Expansion of the Medicare Accelerated and Advance Payment Program will likely provide an immediate injection of liquidity to hospitals that elect to participate. Reportedly, many hospitals throughout the nation have submitted applications under the program, and CMS has said it will review such applications within seven days of receipt to expedite funding. In addition to the liquidity boost, the 20% increase in Medicare reimbursement for coronavirus cases will cover some of the costs associated with the outbreak.

Larger systems will be better able to weather the pandemic

Factors in addition to the federal aid package will also support credit quality. Larger systems which have regional diversification and strong absolute and relative liquidity will be better able to weather the pandemic. Many larger systems have access to capital through the form of bank lines or revolvers, while others have quickly established new bank lines of credit. For example, lines of credit helped to establish a ratings floor with a stable outlook when we downgraded [University of Pittsburgh Medical Center \(UPMC\)](#) to A2 stable from A1 negative (approximately \$21 billion in revenue). The stable outlook also reflects some benefits that UPMC will garner from the CARES Act. Any reimbursement of coronavirus costs will help offset expenses, though likely not enough to make hospitals whole.

Bigger systems will also benefit from other factors. Some academic medical centers, for example, will find a source of credit strength in being owned by large universities and thereby having a "parent" as a liquidity source.

This publication does not announce a credit rating action. For any credit ratings referenced in this publication, please see the ratings tab on the issuer/entity page on www.moody's.com for the most updated credit rating action information and rating history.

Smaller hospitals face greater liquidity difficulties

Smaller, single-site hospitals may face near-term liquidity challenges because many are unable to access alternative capital sources such as bank lines. Even those hospitals with only a few COVID-19 patients may suffer significantly because of the suspension of elective services. The impact of these suspensions will likely be more pronounced for small hospitals than for larger systems with more flexibility in their operations. If these credit effects materialize, ratings will face the possibility of negative outlooks or downgrades, with the degree of movement depending on the severity of a hospital's situation.

Extent of credit impact will also depend on length of the coronavirus outbreak

A key uncertainty underlying the CARES Act is the duration of the pandemic. If the outbreak is prolonged and there is no additional legislation passed to support hospitals, the impact on credit will be all the greater.

Moody's related publications

Outlook

- » [Not-for-profit and public healthcare - US: Outlook changes to negative as coronavirus accentuates cash flow constraints](#), March 18, 2020

Sector Comment

- » [Coronavirus and oil price shocks: managing ratings in turbulent times](#), March 17, 2020

© 2020 Moody's Corporation, Moody's Investors Service, Inc., Moody's Analytics, Inc. and/or their licensors and affiliates (collectively, "MOODY'S"). All rights reserved.

CREDIT RATINGS ISSUED BY MOODY'S INVESTORS SERVICE, INC. AND/OR ITS CREDIT RATINGS AFFILIATES ARE MOODY'S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND MATERIALS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY'S (COLLECTIVELY, "PUBLICATIONS") MAY INCLUDE SUCH CURRENT OPINIONS. MOODY'S INVESTORS SERVICE DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT OR IMPAIRMENT. SEE MOODY'S RATING SYMBOLS AND DEFINITIONS PUBLICATION FOR INFORMATION ON THE TYPES OF CONTRACTUAL FINANCIAL OBLIGATIONS ADDRESSED BY MOODY'S INVESTORS SERVICE CREDIT RATINGS. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS, NON-CREDIT ASSESSMENTS ("ASSESSMENTS"), AND OTHER OPINIONS INCLUDED IN MOODY'S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. MOODY'S PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY'S ANALYTICS, INC. AND/OR ITS AFFILIATES. MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY'S ISSUES ITS CREDIT RATINGS, ASSESSMENTS AND OTHER OPINIONS AND PUBLISHES ITS PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.

MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS, AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS OR PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY'S PRIOR WRITTEN CONSENT.

MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY ANY PERSON AS A BENCHMARK AS THAT TERM IS DEFINED FOR REGULATORY PURPOSES AND MUST NOT BE USED IN ANY WAY THAT COULD RESULT IN THEM BEING CONSIDERED A BENCHMARK.

All information contained herein is obtained by MOODY'S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided "AS IS" without warranty of any kind. MOODY'S adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources MOODY'S considers to be reliable including, when appropriate, independent third-party sources. However, MOODY'S is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing its Publications.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is advised in advance of the possibility of such losses or damages, including but not limited to: (a) any loss of present or prospective profits or (b) any loss or damage arising where the relevant financial instrument is not the subject of a particular credit rating assigned by MOODY'S.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability for any direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded) on the part of, or any contingency within or beyond the control of, MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY CREDIT RATING, ASSESSMENT, OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY'S IN ANY FORM OR MANNER WHATSOEVER.

Moody's Investors Service, Inc., a wholly-owned credit rating agency subsidiary of Moody's Corporation ("MCO"), hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody's Investors Service, Inc. have, prior to assignment of any credit rating, agreed to pay to Moody's Investors Service, Inc. for credit ratings opinions and services rendered by it fees ranging from \$1,000 to approximately \$2,700,000. MCO and Moody's investors Service also maintain policies and procedures to address the independence of Moody's Investors Service credit ratings and credit rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold credit ratings from Moody's Investors Service and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at www.moody.com under the heading "Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy."

Additional terms for Australia only: Any publication into Australia of this document is pursuant to the Australian Financial Services License of MOODY'S affiliate, Moody's Investors Service Pty Limited ABN 61 003 399 657 AFSL 336969 and/or Moody's Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to "wholesale clients" within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY'S that you are, or are accessing the document as a representative of, a "wholesale client" and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to "retail clients" within the meaning of section 761G of the Corporations Act 2001. MOODY'S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors.

Additional terms for Japan only: Moody's Japan K.K. ("MJJK") is a wholly-owned credit rating agency subsidiary of Moody's Group Japan G.K., which is wholly-owned by Moody's Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody's SF Japan K.K. ("MSFJ") is a wholly-owned credit rating agency subsidiary of MJJK. MSFJ is not a Nationally Recognized Statistical Rating Organization ("NRSRO"). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJJK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJJK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJJK or MSFJ (as applicable) have, prior to assignment of any credit rating, agreed to pay to MJJK or MSFJ (as applicable) for credit ratings opinions and services rendered by it fees ranging from JPY125,000 to approximately JPY250,000,000.

MJJK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.

CLIENT SERVICES

Americas	1-212-553-1653
Asia Pacific	852-3551-3077
Japan	81-3-5408-4100
EMEA	44-20-7772-5454